Moin Vera1, Steven Le1, Shih-Hsin Kan1, Hermes Garban2, David Naylor3, Anton Mlikotic4, Ilkka Kaitila5, Paul Harmatz6, Agnes Chen1, Patricia Dickson1. 1. Department of Pediatrics, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California. 2. Department of Internal Medicine, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California. 3. Department of Neurology, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California. 4. Department of Radiology, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California. 5. Departments of Medical Genetics and Pediatrics, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland. 6. Department of Pediatrics, Children's Hospital and Research Center Oakland, Oakland, California.
Abstract
BACKGROUND: Intrathecal (IT) enzyme replacement therapy with recombinant human α-L-iduronidase (rhIDU) has been studied to treat glycosaminoglycan storage in the central nervous system of mucopolysaccharidosis (MPS) I dogs and is currently being studied in MPS I patients. METHODS: We studied the immune response to IT rhIDU in MPS I subjects with spinal cord compression who had been previously treated with intravenous rhIDU. We measured the concentrations of specific antibodies and cytokines in serum and cerebrospinal fluid (CSF) collected before monthly IT rhIDU infusions and compared the serologic findings with clinical adverse event (AE) reports to establish temporal correlations with clinical symptoms. RESULTS: Five MPS I subjects participating in IT rhIDU trials were studied. One subject with symptomatic spinal cord compression had evidence of an inflammatory response with CSF leukocytosis, elevated interleukin-5, and elevated immunoglobulin G. This subject also complained of lower back pain and buttock paresthesias temporally correlated with serologic abnormalities. Clinical symptoms were managed with oral medication, and serologic abnormalities were resolved, although this subject withdrew from the trial to have spinal decompressive surgery. CONCLUSION: IT rhIDU was generally well tolerated in the subjects studied, although one subject had moderate to severe clinical symptoms and serologic abnormalities consistent with an immune response.
BACKGROUND: Intrathecal (IT) enzyme replacement therapy with recombinant human α-L-iduronidase (rhIDU) has been studied to treat glycosaminoglycan storage in the central nervous system of mucopolysaccharidosis (MPS) I dogs and is currently being studied in MPS Ipatients. METHODS: We studied the immune response to IT rhIDU in MPS I subjects with spinal cord compression who had been previously treated with intravenous rhIDU. We measured the concentrations of specific antibodies and cytokines in serum and cerebrospinal fluid (CSF) collected before monthly IT rhIDU infusions and compared the serologic findings with clinical adverse event (AE) reports to establish temporal correlations with clinical symptoms. RESULTS: Five MPS I subjects participating in IT rhIDU trials were studied. One subject with symptomatic spinal cord compression had evidence of an inflammatory response with CSF leukocytosis, elevated interleukin-5, and elevated immunoglobulin G. This subject also complained of lower back pain and buttock paresthesias temporally correlated with serologic abnormalities. Clinical symptoms were managed with oral medication, and serologic abnormalities were resolved, although this subject withdrew from the trial to have spinal decompressive surgery. CONCLUSION: IT rhIDU was generally well tolerated in the subjects studied, although one subject had moderate to severe clinical symptoms and serologic abnormalities consistent with an immune response.
Authors: Dyane Auclair; John Finnie; Steven U Walkley; Joleen White; Timothy Nielsen; Maria Fuller; Alphonsus Cheng; Charles A O'Neill; John J Hopwood Journal: Pediatr Res Date: 2012-01 Impact factor: 3.756
Authors: E D Kakkis; M F McEntee; A Schmidtchen; E F Neufeld; D A Ward; R E Gompf; S Kania; C Bedolla; S L Chien; R M Shull Journal: Biochem Mol Med Date: 1996-08
Authors: James C Dodge; Jennifer Clarke; Christopher M Treleaven; Tatyana V Taksir; Denise A Griffiths; Wendy Yang; Jonathan A Fidler; Marco A Passini; Kenneth P Karey; Edward H Schuchman; Seng H Cheng; Lamya S Shihabuddin Journal: Exp Neurol Date: 2008-11-14 Impact factor: 5.330
Authors: E Kakkis; M McEntee; C Vogler; S Le; B Levy; P Belichenko; W Mobley; P Dickson; S Hanson; M Passage Journal: Mol Genet Metab Date: 2004 Sep-Oct Impact factor: 4.797
Authors: Lalitha R Belur; Alexa Temme; Kelly M Podetz-Pedersen; Maureen Riedl; Lucy Vulchanova; Nicholas Robinson; Leah R Hanson; Karen F Kozarsky; Paul J Orchard; William H Frey; Walter C Low; R Scott McIvor Journal: Hum Gene Ther Date: 2017-04-20 Impact factor: 5.695
Authors: Daniel A Wolf; Sharbani Banerjee; Perry B Hackett; Chester B Whitley; R Scott McIvor; Walter C Low Journal: Expert Opin Drug Deliv Date: 2014-12-16 Impact factor: 6.648
Authors: Christian Hinderer; Peter Bell; Jean-Pierre Louboutin; Nathan Katz; Yanqing Zhu; Gloria Lin; Ruth Choa; Jessica Bagel; Patricia O'Donnell; Caitlin A Fitzgerald; Therese Langan; Ping Wang; Margret L Casal; Mark E Haskins; James M Wilson Journal: Mol Genet Metab Date: 2016-06-08 Impact factor: 4.797
Authors: Patricia I Dickson; Ilkka Kaitila; Paul Harmatz; Anton Mlikotic; Agnes H Chen; Alla Victoroff; Merry B Passage; Jacqueline Madden; Steven Q Le; David E Naylor Journal: Mol Genet Metab Date: 2015-07-26 Impact factor: 4.797
Authors: Michael Frohbergh; Yi Ge; Fanli Meng; Nesrin Karabul; Alexander Solyom; Alon Lai; James Iatridis; Edward H Schuchman; Calogera M Simonaro Journal: PLoS One Date: 2014-06-25 Impact factor: 3.240